PharmaShots
magazine

INNOVATIVE MINDS: PSYCHEDELICS IN MEDICINE

Sep'25 Theme

Understanding
PSYCHEDELIC
Medicines

Insights &
INFOGRAPHICS
Psychedelics Drugs

What's on
BIO-TRENDS
Innovative Minds: Psychedelics in Medicine

SEP | 2025
VOL 4 | ISSUE 09

TABLE OF

CONTENTS

ABRIDGED

In August, PharmaShots was swayed by the constant influx of life science and industry updates. The month remained pivotal for us as we unlocked several media partnerships to cover events such as the Discovery & Development Summit, HLTH USA 2025, 2025 Biopharma Deals, Pharmaceutical Automation and Digitalisation Congress (AUTOMA+) 2025, Drug Discovery and Innovation Programme 2025, Clinical Trials Operations DACH 2025, and Peptides & Complex Generics Symposium.

The key highlight remained the CXO Talks Podcast featuring Thomas Chalberg & Annahita Keravala from Genascence. Our most read Top 20 section featured a meticulously crafted report on R&D Spending Biopharma Companies. The Know Your Investor report focused on Venrock Healthcare Capital Partners, a venture capital fund focused on investments in both publicly and privately held healthcare companies. The Disease of the Month report featured a comprehensive take on Rosacea, a chronic skin condition characterized by facial redness, acne-like breakouts, and flushing.

Like every month, we published our Monthly digests on Key Biosimilars, FDA & EMA approvals, and Designations to keep our readers up to date on the developments in the industry.

About the Theme: Innovative Minds: Psychedelics in Medicine

Medical psychedelics are a fascinating field that modern science has yet to comprehend completely. Researchers are still digging up, trying to find evidence-based outcomes to tap into a whole new world to psychiatry and mental health medicines. The September Edition unearths a brand-new perspective on psychedelics through engaging articles, illustrative infographics, trailing BioTrends, illuminating regulatory updates, and a few amazing facts to keep you hooked throughout the magazine.

The October Edition of PharmaShots Magazine will focus on Food and Wellness, and the November Edition will revolve around Radiopharma Innovations in Oncology.

IN MEDICINE

Psychedelics in medicine remains one of the most debated topics in healthcare. While some highlight their potential benefits in treating anxiety, addiction, and PTSD, others raise concerns about the lack of standardized protocols, the early stage of science, and possible long-term health risks. Additionally, spiritual and religious perspectives often cast doubt on psychedelic therapy when compared with evidence-based treatments. This article examines both the promise and the skepticism surrounding psychedelics.

Clinical Research on Psychedelics

Anxiety & Depression

The U.S. FDA has granted breakthrough therapy designations for psilocybin in treatment-resistant depression (2018) and major depressive disorder (2019), as well as MDMA for PTSD. These approvals highlight the growing interest in psychedelics as alternatives for hard-to-treat conditions.

Obsessive-Compulsive Disorder (OCD)

One of the earliest studies on psilocybin dates back to 1959, involving patients with OCD. Initial results showed symptom relief that later resurfaced over time. Since then, ongoing research has explored psilocybin's therapeutic potential, with animal models demonstrating encouraging outcomes following single administrations.

Substance Use Disorders

Classic psychedelics such as LSD, mescaline, psilocybin, and ayahuasca have been studied for their role in treating alcohol and tobacco use disorders, among others. Non-classic psychedelics, including ketamine, ibogaine, and MDMA, are also showing promise in substance use treatment, broadening the therapeutic landscape.

Migraine & Cluster Headaches

Clinical studies with psilocybin and LSD have produced meaningful results in managing migraines and cluster headaches, offering potential new options for patients who struggle with these debilitating conditions.

Biases and Challenges in Psychedelic Medicine

Despite growing enthusiasm, significant challenges remain. Relapses following psychedelic therapy raise concerns about long-term effectiveness. Clinical data has also reported new psychiatric diagnoses and the worsening of existing symptoms in some patients, raising questions about safety. Furthermore, the strong narrative of promise often overshadows negative outcomes, leading to concerns that psychedelics are being overhyped.

INFOGRAPHICS

FROM COUNTERCULTURE TO CLINICAL CARE

PSILOCYBIN

Source: 200 species of magic mushrooms

Psychedelic Class: Tryptamine

MoA: 5-HT2A receptor agonist

Indications: Depression, Anxiety, PTSD, OCD, Cluster headaches, Alzheimer's disease

Industry-Funded Trials: 35+ trials across the US, UK, EU, Canada & beyond

N, N-DIMETHYLTRYPTAMINE

Source: Chemically synthesized or naturally derived from Mimosa tenuiflora (Jurema)

Psychedelic Class: Tryptamine

MoA: 5-HT2A receptor agonist

Indications: Depression & Addiction

Industry-Funded Trials: 10+ trials across Netherlands, the US, the UK & beyond

LYSERGIC ACID DIETHYLAMIDE

Source: Semisynthetic drug obtained from ergot

Psychedelic Class: Lysergamide

MoA: 5-HT2A receptor agonist



Indications: Depression, Anxiety, Addiction, Cluster headaches, Alzheimer's disease, Tourette's syndrome, ADHD

Industry-Funded Trials: 3 trials across Netherlands, Switzerland & the UK (Eleusis Therapeutics & Mind Medicine)

PharmaShots
Illuminate. Innovate. Inspire.

FROM COUNTERCULTURE TO CLINICAL CARE

3,4-METHYLENEDIOXYMETHAMPHETAMINE

Source: Synthetic drug

Psychedelic Class: Phenethylamine

MoA: Increases serotonin, dopamine, and norepinephrine release and reuptake

Indications: PTSD, Autism spectrum disorder, Obesity, Narcolepsy and ADHD

Industry-Funded Trials: 20+ trials across the US, UK, Switzerland, Canada & beyond

KETAMINE

Source: Synthetic drug

MoA: Noncompetitive NMDA receptor antagonist

Psychedelic Class: Arylcyclohexylamines

Indications: Depression, Bipolar disorder, Anxiety, Suicidal ideation, Addiction, Autism spectrum disorder, Chronic pain, Arthritis & Fibromyalgia

Industry-Funded Trials: 120+ trials across the US, China, Australia & beyond

IBOGAINE

Source: Root Bark of Tabernanthe iboga

Psychedelic Class: Tryptamine

MoA: Blocks NMDA & nicotinic receptors; Modulates opioid & serotonin systems



Indications: Opioid addiction, alcohol use disorder, nicotine dependence, cocaine and stimulant dependence

Industry-Funded Trials: P-I/II for Opioid Withdrawal (atai Therapeutics)

PharmaShots
Illuminate. Innovate. Inspire.

REGULATORY

Psychedelic Drugs: Considerations for Clinical Investigations

Guidance for Industry

Important regulations for the clinical investigation and development of psychedelic drugs include requirements spanning chemistry, manufacturing, nonclinical safety, clinical pharmacology, abuse potential assessment, and clinical trial conduct.

Regulatory Overview

Clinical investigation of psychedelic drugs is subject to the same strict FDA regulations and evidentiary standards as other drugs. Sponsors must submit an Investigational New Drug (IND) application and provide detailed information on every aspect of drug development for each phase, whether the trials are for research or intended for marketing approval.

Chemistry, Manufacturing, and Controls

- Sufficient information about identification, quality, purity, and strength of the drug substance and strength of the drug substance and product is mandatory for all clinical trial phases, and drugs must be manufactured in compliance with Current Good Manufacturing Practice (CGMP) under section 501(a)(2)(b) of the Food, Drug, and Cosmetic Act.
- For phase 2 and beyond, stricter CGMP regulations (21 CFR part 211) apply.

Nonclinical Safety

- Nonclinical programs should follow ICH guidance M3(R2), but certain psychedelics may initiate INDs without typical animal toxicology if there is extensive prior human exposure and no serious safety concerns.
- Animal safety studies are required unless there is adequate published human data, especially for drugs with unknown clinical exposure.
- Special consideration is needed for serotonin (5-HT) subtypes, as 5-HT2B agonists must be closely examined for heart valvulopathy.

Clinical Pharmacology

- Drugs must have their pharmacokinetics, pharmacodynamics, dose-response, and drug-drug interaction profiles robustly characterized, including evaluation of the effect of a high-fat meal for oral drugs.
- Subjects with preexisting valvular heart disease or pulmonary hypertension should be excluded if the drug is a 5-HT2B agonist.

Abuse Potential Assessment

- All psychedelics require a thorough abuse potential evaluation as part of safety assessment, including submission of scheduling proposals for drugs under the Controlled Substances Act.

REGULATORY

- Schedule I substances demand compliance with DEA registration, handling, and research regulations (21 CFR part 1301).
- Protocols for abuse assessment studies should be reviewed by the FDA before initiation.

Clinical Trial Conduct

- Adequate and well-controlled clinical studies are needed to support efficacy and safety, but unique challenges exist due to perceptual disturbances and functional unblinding in psychedelic trials.
  - Alternatives to inert placebos may be considered, such as subperceptual doses or active comparator drugs.
  - Robust safety monitoring is required: two session monitors, including an independently licensed mental health professional, with a physician on-call if the lead monitor is not one.
- Informed consent should explicitly mention possible changes to perception, cognition, and judgment.
- Long-term follow-up is often needed to evaluate durability of treatment, and safety assessments (including cardiac monitoring for certain drugs) may be required during and after trials.

Risk Management and Public Health

- Risk mitigation strategies must be detailed for clinical studies and post-marketing. The FDA may consider additional risk evaluation and mitigation strategies (REMS) if routine measures are insufficient.
- Public health effects, such as risk of substance use disorder and nonmedical use, are factored into the drug's benefit-risk assessment.

DID YOU KNOW ?

In 2024, the global psychedelic drugs market was valued at $3.63B and is projected to grow at a 13.68% CAGR, reaching $10.11B by 2032

BIO-TRENDS

Innovative Minds: Psychedelics in Medicine

Psychedelics are a group of substances that profoundly change a person's perception, mood, and cognitive processes, often leading to intense sensory experiences and a transformative shift in consciousness. Drugs such as LSD, psilocybin, ayahuasca mescaline etc are psychedelics that have been used throughout history in spiritual and ritual contexts and are now being studied for their therapeutic potential in addressing mental illnesses. Although psychedelics are classified as Schedule I substances under the 1971 UN Convention because of their potential for misuse and limited recognized medical value, a wave of recent research is revealing promising therapeutic benefits.



As of 2024, there is a strong global effort to explore the therapeutic potential of psychedelics, with over a thousand clinical studies underway involving substances like LSD and MDMA. Funding comes from various sources, including government agencies like the NIH and the Department of Defense, private industry, and numerous universities and organizations.

BIO-TRENDS

Expedited Pathways for Psychedelic Therapies in Global Markets

Building on this scientific foundation, various regulatory bodies have given special designations to psychedelic drugs to speed up their development for treating mental conditions. In the US, the FDA has granted several Breakthrough Therapy Designations, including MDMA for PTSD in 2017, psilocybin for major depressive disorder in 2019, treatment-resistant depression in 2018, and more recently, an LSD formulation for generalized anxiety disorder in 2024. There is also a psilocybin analog, CYB003, for major depressive disorder in 2024. Outside the US, formal designations are less common. However, regulatory bodies like Health Canada provide options such as the Special Access Program for medical use on a case-by-case basis. Australia's TGA and European regulators are creating frameworks to support controlled access to therapy, which shows the growing global recognition of the clinical potential of psychedelics in regulated settings.

Global Policy Advances in Psychedelic Therapies

Recent policy development reflects expanding acceptance of psychedelics for medical use. Australia became the first country to authorize the medical use of psilocybin for treatment-resistant depression and MDMA for PTSD as of July 2023. Quebec and Canada approved health coverage for psilocybin-assisted psychotherapy in 2022. Meanwhile, Colorado has decriminalized personal use and possession of certain natural psychedelics and allows their use in licensed facilities, with plans to increase substance types such as DMT, ibogaine, and mescaline by 2026.

Conclusion:

The shifting landscape of psychedelic research, regulatory progress, and policy change shows a bright future for such therapies in mental health practice. As clinical data increase and legal regulations evolve across the world, psychedelics are set to become part of mainstream treatment options for disorders such as depression, PTSD, and anxiety, providing revamped hope to patients and transforming the mental health sector.

CATALYST TO

WATCH OUT FOR

Stay informed on monthly PDUFA action dates with Octavus Consulting's Catalyst!
Empowering data and decision-making with advanced competitive intelligence and market research, Octavus Consulting helps companies drive innovation and provides them with a competitive edge.

Watch out for the upcoming PDUFA dates in **September:**

- Corstasis Therapeutics awaits the approval (PDUFA: Sep 14, 2025) of RSQ-777 for edema associated with congestive heart failure, as well as liver and kidney disease
- Incyte awaits the approval (PDUFA: Sep 19, 2025) of Opzelura for atopic dermatitis
- Scholar Rock awaits the approval (PDUFA: Sep 22, 2025) of Apitegromab for spinal muscular atrophy
- Merck awaits the approval (PDUFA: Sep 23, 2025) of Subcutaneous Keytruda for NSCLC
- Crinetics Pharmaceuticals awaits the approval (PDUFA: Sep 25, 2025) of Paltusotine for acromegaly
- Sanofi awaits the approval (PDUFA: Sep 28, 2025) of tolebrutinib for non-relapsing secondary progressive multiple sclerosis
- Fortress Biotech awaits the approval (PDUFA: Sep 30, 2025) of CUTX-101 for Menkes disease

READ MORE

UPCOMING

CONFERENCES

Conferences to Watch in October 2025 – Curated by Octavus Consulting

At Octavus Consulting, it spotlight the key conferences in October 2025 that are essential for staying ahead in the competitive landscape. These events offer invaluable opportunities to gain insights into industry trends, assess competitor strategies, and benchmark performance. With deep expertise in competitive intelligence and market research, Octavus Consulting empowers organizations to make informed decisions and accelerate innovation—helping them stay ahead of the curve.

About Octavus Consulting:

Octavus is a global consulting firm, specializing in holistic market solutions for diverse Life science sectors such as Biopharma, MedTech, Nutraceuticals, Cosmetics, Diagnostics, Digital health, Animal health, and Healthcare start-ups.

Octavus offers tailored services including competitive intelligence, conference coverage, congress intelligence, market research and data analytics. Contact Octavus Consulting at bd@octavusconsulting.com



READ MORE

UPCOMING CONFERENCES

OCTOBER 2025

11-14 OCT	AAO-HNSF ANNUAL MEETING & OTO EXPERIENCE — INDIANAPOLIS, US	14-18 OCT	ASHG American Society of Human Genetics — BOSTON, US	16-19 OCT	EANO European Association of Neuro-Oncology — PRAGUE, CZECH REPUBLIC
17-20 OCT	American Academy of Ophthalmology — ORLANDO, US	17-21 OCT	ESMO Good Science Better Medicine Best Practice — BERLIN, GERMANY	19-22 OCT	CHEST — CHICAGO, US
19-22 OCT	IDWeek 2025 — ATLANTA, US	20-25 OCT	AACAP 2025 — CHICAGO, US	22-25 OCT	#aapmr25 — UTAH, US
22-26 OCT	AACR American Association for Cancer Research — BOSTON, US	23-25 OCT	20TH ANNUAL Cardiometabolic Health Congress — BOSTON, US	23-26 OCT	20 25 Canadian Cardiovascular Congress — QUÉBEC, CANADA
23-25 OCT	North American Cystic Fibrosis Conference — SEATTLE, US	23-25 OCT	IVC 2025 — ORLANDO, US	23-25 OCT	WOC 2025 World Obesity and Weight Management Congress — ORLANDO, US
24-29 OCT	ACR American College of Rheumatology — CHICAGO, US	24-29 OCT	ACG 2025 — PHOENIX, US	25-28 OCT	SMR — AMSTERDAM, NETHERLANDS
25-28 OCT	CRF TCT — SAN FRANCISCO, US	25-29 OCT	asrm American Society for Reproductive Medicine — SAN ANTONIO, US	30 OCT-2 NOV	JDDW 2025 KOBE — KOBE, JAPAN

OCTAVUSCONSULTING.COM

OCTAVUS CONSULTING

BD@OCTAVUSCONSULTING.COM

OCTAVUS CONSULTING Data.Insights.Decisions.

READ MORE

CONFERENCES

Contact us for these Cardiology Conferences Coverage at bd@octavusconsulting.com

In the world of biopharmaceuticals, medical conferences remain key to mainstreaming cutting-edge innovation, addressing unmet medical needs, and highlighting challenges facing the industry. Cardiology continues to be one of the most explored fields in healthcare, with a number of clinical trials currently underway for lifesaving therapies. ESC 2025, NEVASH and CIRSE Congress are among the several conferences that attract researchers, pharma professionals, regulatory experts, and investors, driving innovation in cardiology care.

These global events promote collaboration, knowledge sharing, and the development of innovative treatment strategies.

For life sciences companies, these conferences are a strategic opportunity to gather competitive insights, evaluate industry trends, and measure peer performance. With strong capabilities in competitive intelligence and healthcare research, Octavus Consulting helps clients turn information into actionable strategies—driving smarter decisions and faster innovation.

READ MORE »

COVERAGE



Conference Coverage Series: ESC 2025 Annual Meeting!

ESC Congress 2025 focused on Global Health, with key highlights including cutting-edge science and new-age technologies in cardiology care. New and updated clinical guidelines on dyslipidemias, myocarditis/pericarditis, valvular heart disease, cardiovascular disease, and pregnancy.

The congress highlighted late-breaking trials and clinical data, including the STEER study by Novo Nordisk, P-III VICTOR & VICTORIA studies by Merck, and the BaxHTN trial by AstraZeneca, among others.
ESC Congress 2025 also emphasized the significance of understanding cardiovascular risk factors.

READ MORE

Reach out to us if you are looking for congress coverage, planner creation, and abstract analysis at bd@octavusconsulting.com

DID YOU KNOW ?

In 2024, the synthetic compounds segment dominated the psychedelic drugs market with a 55% share, attributed to their reliability, scalability, and regulatory compliance

DEALS INSIGHTS

Neurology R&D Partnerships, M&A, Ventures and IPOs – H1 2025 Review

Neurology in H1 2025 reflected a selective yet strategic landscape, with slower partnering, fewer but larger acquisitions, and steady venture funding.

Key R&D partnerships included GSK's April 2025 deal with ABL Bio to develop antibody- and RNA-based therapies using the Grabody-B BBB platform, providing $50 million upfront and up to $2.7 billion in milestones and royalties; Eli Lilly's April 2025 collaboration with Sangamo on its STAC-BBB AAV capsid platform with $18 million upfront and up to $1.4 billion in fees and milestones; Biogen's May 2025 agreement with City Therapeutics on RNAi-based CNS therapies with $46 million upfront ($16 million cash, $30 million convertible notes), an undisclosed option fee, and up to $1 billion in milestones plus royalties; Angelini Pharma's May 2025 license of GRIN's radiprodil for $50 million upfront, up to $520 million in milestones, plus royalties.



READ MORE

About DealForma:

DealForma maintains the most comprehensive database for biopharma deal benchmarking in a modern platform that combines highly curated licensing, venture, and M&A data, an intuitive interface, and biopharma-specific categories for indications, modalities, targets, and stages of drug development. The DealForma database is trusted by biotech, pharma, investment banks, and advisory firms for accurate data on industry activity.

MONTHLY

RECAP

TOP 20

Top 20 R&D Spending Biopharma Companies of 2025

- Research and Development (R&D) serves as the driving force behind groundbreaking therapeutic innovations, laying the foundation for advancements that transform patient health and overall well-being
- The global Top 20 pharmaceutical leaders spent ~$180B in 2024, with Merck & Co. contributing the most with a whopping $17.93B, followed by Johnson & Johnson ($17.23B) and Roche ($14.43B)
- PharmaShots brings a concise report on the Top 20 R&D Spending Biopharma Companies, along with their focus areas

READ MORE »

DID YOU KNOW ?

In 1970, Ketamine was approved by the US FDA as an anesthetic with esketamine (Spravato) approval in 2019 for treatment-resistant depression. In Aug'25, PharmaTher's KETARx gained FDA approval, broadening its therapeutic use in surgical pain management

Key Biosimilars Events of August 2025

- Biosimilars are developed to be highly similar of approved biologics in terms of safety, purity, and potency
- Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients
- Alvotech and Advanz Pharma Receive the EC's Approval for Mynzepli (Biosimilar, Eylea). Our team at PharmaShots has summarized 11 key events of the biosimilar space of August 2025

READ MORE

OF THE MONTH

Disease of the Month – Rosacea

- Rosacea is a chronic skin condition characterized by facial redness, acne-like breakouts, and flushing. It may cause enlarged blood vessels and small pus pus-filled bumps
- PharmaShots' Disease of the Month report aims to educate a broad audience about health conditions that affect communities worldwide. These reports provide a comprehensive overview of disease, including their characteristics, types, symptoms, diagnostic approaches, available treatment options, epidemiology, market size, ongoing clinical trials, active patient advocacy groups (PAGs), and inspiring patient stories
- For a detailed landscape analysis and customized insights on Rosacea, contact our team at connect@pharmashots.com

READ MORE

Understanding Rosacea

Rosacea is a chronic, inflammatory skin condition that primarily affects the face, causing symptoms like redness, visible blood vessels, and small, pus-filled bumps. It typically presents in cycles of flare-ups and remissions and can also involve eye symptoms or skin thickening on the nose. While there is no cure, management involves identifying and avoiding triggers like sun exposure, stress, and alcohol, and using medications such as gels, lotions, or creams to control symptoms.

Symptoms

- Persistent Facial Redness
- Visible Blood Vessels
- Flushing
- Acne-like bumps
- Pimples

DESIGNATIONS



New Drug Designations: July 2025

- PharmaShots' Designation Report offers a concise overview of the latest drug and device designations granted by major regulatory authorities, including the FDA, EMA, MHLW, Health Canada, and NMPA.
- The July 2025 edition covers designations awarded to 47 drugs and 3 medical devices, comprising 23 small molecules, 9 biologics, 8 cell and gene therapies, and 3 medical devices, among others.
- Key highlights this month include BeOne Medicines' BGB-16673 receiving both Prime and Orphan Drug status



READ MORE

DID YOU KNOW ?

Psychedelics are gaining traction in mental health treatment, with over 200 global clinical trials on psilocybin underway

NEW DRUG APPROVALS

The US FDA New Drug Approvals in July 2025

- PharmaShots has compiled a list of US FDA-approved drugs in the month of July 2025
- The US FDA has approved a total of 6 new drugs, including 5 new molecular entities and 1 biologic, leading to the treatment of patients and advances in the pharmaceutical industry
- The major highlighted drug was Regeneron's Lynozyfic, securing FDA approval for tR/R Multiple Myeloma

READ MORE

EMA Marketing Authorization of New Drugs in July 2025

- The EMA's CHMP has granted positive opinions and approvals to 3 Biologics and 10 new chemical entities in July 2025, leading to treatments for patients and advances in the healthcare industry
- The major highlighted drug was Roche's Itovebi Secures the EC's Approval for PIK3CA-mutated Breast Cancer
- PharmaShots has compiled a list of 13 drugs that have been granted positive opinions and approvals by the EC, respectively

READ MORE

DID YOU KNOW ?

In Aug'25, AbbVie secured a deal from Gilgamesh Pharmaceuticals worth up to $1.2 billion for the rights to bretisilocin, a fast-acting compound with similarities to psilocybin and strong therapeutic potential

KNOW

YOUR INVESTOR

Know Your Investor: Venrock Healthcare Capital Partners (August'25 Edition)

- Welcome to the August edition of Know Your Investor, featuring leading venture capital firms fuelling innovation in healthcare and life sciences
- This edition spotlights Venrock Healthcare Capital Partners, a venture capital fund focused on investments in both publicly and privately held healthcare companies
- In 2024, Venrock Healthcare Capital Partners invested approximately $4.56B across six funding rounds, adding 32 healthcare and biotech companies to its growing portfolio. For the full report, contact us at connect@pharmashots.com.



About Venrock Healthcare Capital Partners

- Venrock Healthcare Capital Partners is a specialized venture capital fund operating under the prestigious Venrock umbrella. Since its inception in 2009, it has become a powerhouse investor in the healthcare and life sciences domain—deploying capital across private and public markets, supporting breakthrough innovations, and generating impactful outcomes through both scale and strategic focus.

READ MORE

DID YOU KNOW ?

In Oct'21, Johns Hopkins received the first-ever federal grant for psychedelic research in 50 years

THOUGHTSPOT

Trends Shaping the Biopharma Industry in 2025

READ MORE

Trends Shaping the Peptide Therapeutics Market in 2025

READ MORE

GLOSSARY &

ABBREVIATIONS

GLOSSARY

- **Mescaline:** Naturally occurring psychoactive substance found in several species of cacti
- **Psilocybin:** Naturally occurring tryptamine alkaloid found in more than 200 species of mushrooms
- **Ayahuasca:** A potent psychoactive brew that produces intense psychological and spiritual experiences
- **Tryptamine:** A naturally occurring indolamine metabolite comprising a broad class of classical or serotonergic hallucinogens
- **Agonist:** A substance that binds to a receptor and activates it
- **Fibromyalgia:** A chronic condition characterized by widespread musculoskeletal pain
- **Pharmacology:** A scientific study of drugs and chemicals and how they affect living organisms
- **Mitigate:** Lessen the effect of something
- **Ketamine:** A cyclohexanone-derived general anesthetic and NMDA receptor antagonist with analgesic and hallucinogenic properties
- **Expedite:** Make something happen more quickly or efficiently
- **Dyslipidemia:** A condition characterized by abnormal or impaired levels of lipids (fats) in the blood, such as cholesterol and triglycerides
- **Myocarditis:** An inflammation of the heart muscle, the myocardium, which can impair the heart's ability to pump blood effectively
- **Pericarditis:** An inflammation of the pericardium, the two-layered sac surrounding the heart
- **Rosacea:** A common skin condition that causes flushing or long-term redness on the face

ABBREVIATIONS

- **PTSD:** Post-traumatic stress disorder
- **LSD:** Lysergic acid diethylamide
- **FDA:** Food and Drug Administration
- **MDMA:** 3,4-Methylenedioxymethamphetamine
- **OCD:** Obsessive-compulsive disorder
- **NMDA:** N-methyl-D-aspartate
- **ADHD:** Attention-deficit/hyperactivity disorder
- **cGMP:** Current Good Manufacturing Practices
- **IND:** Investigational New Drug
- **REMS:** Risk Evaluation and Mitigation Strategies
- **CAGR:** Compounded Annual Growth Rate
- **NIH:** National Institutes of Health
- **TGA:** Therapeutic Goods Administration
- **DMT:** Dimethyltryptamine
- **PDUFA:** Prescription Drug User Fee Act
- **NSCLC:** Non-Small Cell Lung Cancer
- **R&D:** Research and Development
- **PAGs:** Patient Advocacy Groups
- **ODD:** Orphan Drug Designation
- **FTD:** Fast Track Designation
- **BTD:** Breakthrough Therapy Designation
- **BDD:** Breakthrough Device Designation
- **RMAT:** Regenerative Medicine Advanced Therapy Designation
- **EMA:** European Medicines Agency
- **CHMP:** Committee for Medicinal Products for Human Use

ABOUT

PHARMASHOTS

- PharmaShots brings curated meaningful news and insights from the media clutter for professionals and decision makers.
- PharmaShots is a leading provider of strategic insights and branding solutions, empowering healthcare leaders to make informed, impactful decisions.
- We specialize in content strategy, market insights, and tailored communication solutions to drive your business objectives.

OUR

TEAM

ADITYA SINGH

HIMANSHU SEHGAL

SAURABH CHAUBEY

TUSHAR MAURYA

PRINCE GIRI

DIPANSHU DIXIT

RIDHI RASTOGI

2025

CALENDAR

PUBLICATION MONTH	THEME	PUBLISHING DATE
Jan	Decoding China’s Healthcare Landscape	09 Jan
Feb	Inside Japan's Healthcare System	13 Feb
Mar	Navigating the Evolving BioPharma CDMO	13 Mar
Apr	3D Bioprinting Revolutionizing the BioPharma Industry	10 Apr
May	Automation and Packaging in BioPharma Industry	08 May
Jun	Redefining Research: The Decentralized Clinical Trials Revolution	12 Jun
Jul	Unlocking the Future: Insights into Regenerative Medicine	10 July
Aug	Inside the Cosmeceutical Revolution: Where Beauty Meets Science	14 Aug
Sep	Innovative Minds: Psychedelics in Medicine	11 Sep
Oct	Food and Wellness: Unveiling the Powerful Connection	09 Oct
Nov	Radiopharma Innovations: Shaping the Future of Oncology	13 Nov
Dec	Transforming Patient Lives: The Impact of KOLs and PAGs	11 Dec

OUR SERVICES

PharmaShots offers a range of services, including Creating, curating, and distributing tailored content to enhance visibility for biopharma and healthcare companies.

01 **Insight Reports:** Actionable market intelligence for informed decision-making in biopharma and healthcare.

02 **Custom Newsletter:** Engaging, branded newsletters tailored to captivate and inform your audience.

03 **Digital Strategy:** Innovative strategies to amplify your brand's presence across digital platforms.

04 **Media Partnerships:** Collaborate with us to expand your reach and influence in the healthcare industry.

05 **Content Creation:** Innovative media solutions for effective brand outreach

06 **Content Distribution:** Strategically curated and distributed content to target your ideal audience.

07 **Interviews & Guest Posts:** Our Interview service ranges from Viewpoint, Exclusive, and Spotlight Interviews. With our Guest Post service, you get a chance to expand your readers base and highlight your insightful articles.

OUR SUBSCRIBERS ARE FROM

ADVERTISE

WITH US

01 Showcase your product and promotion to consumers at varying stages in their purchase cycle

02 Reach the targeted audience that actually intrested in getting your services/products

03 Generate awareness and drive incremental sales

THANK YOU

CONTACT US

PharmaShots
Illuminate. Innovate. Inspire.

PHARMASHOTS MEDIA PRIVATE LIMITED

+91-120 4280707

connect@pharmashots.com

pharmashots.com

First Floor, B-66, Sector 63
Noida, Uttar Pradesh,
INDIA - 201301

Contact Us Here

FOLLOW US